오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; microcrystalline cellulose; hypromellose; sodium bicarbonate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

몰타 - 영어 - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

aristo pharma gmbh wallenroder straße 8–10, 13435, berlin, germany - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

amneal pharma europe limited - ramipril - tablet - ramipril 5 mg - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

amneal pharma europe limited - ramipril - tablet - ramipril 10 mg - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 1.25 mg - agents acting on the renin-angiotensin system

몰타 - 영어 - Medicines Authority

tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - ramipril - tablet - ramipril 2.5 mg - agents acting on the renin-angiotensin system

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium stearylfumarate; pregelatinised maize starch; sodium bicarbonate; croscarmellose sodium; iron oxide yellow; iron oxide red - treatment of hypertension. data are currently not available to support the use of tryzan tabs in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; sodium bicarbonate; croscarmellose sodium; lactose monohydrate; iron oxide yellow - treatment of hypertension. data are currently not available to support the use of tryzan tabs in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.